Please login to the form below

Not currently logged in
Email:
Password:

AZ settles Seroquel patent case

AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US

AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR (quetiapine humarate) in the US.

AZ filed litigation against Accord following the company's submission to the US Food and Drug Administration (FDA) of an abbreviated new drug application for a generic version of the depression treatment.

As part of the agreement, AZ has granted Accord a licence to enter the US market with its generic Seroquel XR on November 1, 2016, or earlier, depending upon certain circumstances.

The drug is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

Remaining Seroquel XR patent infringement litigations are ongoing.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics